Dominic Piscitelli serves as the Chief Financial Officer at ORIC Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing treatments for various cancers. With a robust background in finance and biotechnology, Dominic brings a wealth of experience to his role. Before joining ORIC Pharmaceuticals, he held the position of CFO at Principia Biopharma, where he played a pivotal role in steering the company through its initial public offering (IPO) and subsequent acquisition by Sanofi for approximately $3.7 billion. His strategic financial leadership was instrumental in navigating these critical transitions and maximizing shareholder value. Prior to his tenure at Principia Biopharma, Dominic held senior financial positions at several other notable biotech firms, including Portola Pharmaceuticals and Alios BioPharma. At Portola, he was part of the team that successfully brought the company public and managed its financial strategy through multiple clinical trials and partnerships. His earlier career also includes significant roles at Alios BioPharma, where he contributed to the company's growth and eventual acquisition by Johnson & Johnson. Dominic's career is marked by his ability to drive financial strategy and operational excellence in the biotech industry, making him a valuable asset to ORIC Pharmaceuticals. In his current role at ORIC Pharmaceuticals, Dominic is responsible for overseeing the company's financial operations, including budgeting, financial planning, and investor relations. His leadership is crucial as ORIC advances its pipeline of oncology therapies, with a focus on bringing innovative treatments to patients with unmet medical needs. Under his guidance, ORIC aims to maintain a strong financial position while continuing to invest in research and development. Dominic's expertise and strategic vision are pivotal in helping the company achieve its goals and continue its trajectory toward becoming a leader in cancer treatment innovation.